New triple therapy targets tough breast cancer in phase 3 trial
NCT ID NCT07207070
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 26 times
Summary
This study tests whether adding a new drug (JS105) to two existing drugs (dalpiciclib and fulvestrant) helps people with a certain type of advanced breast cancer live longer without the disease getting worse. The cancer must have a PIK3CA mutation and be hormone-receptor-positive but HER2-negative. About 312 adults aged 18-75 with recurrent or metastatic breast cancer will take part. The goal is to see if the three-drug combo works better than the two-drug combo alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese Acadamy of Medical Sciences and Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Henan Provincial Cancer Hospital
RECRUITINGZhengzhou, Henan, 450003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.